Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allegra Asthma Claim Would Be Key Defense Vs. Forced OTC Switch – Aventis

This article was originally published in The Tan Sheet

Executive Summary

Aventis' Allegra experimental asthma indication would be the best defense against a forced OTC switch of the antihistamine, Chief Operating Officer Richard Markham told analysts during Aventis' R&D day in London June 18
Advertisement

Related Content

FDA Claritin Hypospadia Review Targeted For Summer Completion
Claritin OTC Approval For CIU Would Reduce Off-Label Drug Use – Schering
OTC Claritin Hatch/Waxman Exclusivity Not Expected By Schering-Plough
Second-Generation Antihistamine OTC Labeling Could Resemble Monograph
Second-Generation Antihistamine OTC Labeling Could Resemble Monograph

Topics

Advertisement
UsernamePublicRestriction

Register

PS094165

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel